News

Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals Encapsulated Cell Therapy platform for the potential treatment of Macular Telangiectasia Type 2, with a projected PDUFA goal date from the FDA at the annual ASRS meeting in Stockholm, Sweden.

Jennifer Lim, MD, FARVO, FASRS, gives an update on the phase 2 DAVIO 2 trial comparing EYP-1901 with aflibercept at the annual ASRS meeting in Stockholm, Sweden.

Richard B. Rosen, MD, from the New York Eye and Ear Infirmary of Mount Sinai discussed his presentation on sickle cell retinopathy and the measurement with dynamic OCT angiography and quad-fusion adaptive optics imaging at the annual ASRS meeting in Stockholm, Sweden.

Patrick C. Staropoli, MD, talked about his presentation on the clinical characterization of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa at the annual ASRS meeting in Stockholm, Sweden.

Michael Singer, MD, speaks at the American Society of Retina Specialists meeting

Paolo Antonio Silva, MD, discussed his upcoming ASRS presentation on diabetic retinopathy lesions

Paolo Antonio Silva, MD, discusses his presentation on diabetic retinopathy lesion types and distribution on ultra-widefield imaging and the risk for disease worsening over time at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Danny Mammo, MD, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss the effect of suprachoroidal triamcinolone acetonide in non-infectious uveitis, patients which he is presenting at the American Society of Retina Specialists (ASRS) meeting held in Stockholm, Sweden.

Ahead of the ASRS meeting in Stockholm, Sweden, Danny Mammo, MD, discusses use of suprachoroidal triamcinolone acetonide in non-infectious uveitis

Durga Borkar, MD, MMCi, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss Fas inhibition with ONL-1204 for the treatment of geographic atrophy: First-time results from a phase 1b study, which she is presenting at the ASRS meeting held in Stockholm, Sweden.

Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204 for the treatment of geographic atrophy

The 2-year Phase III data presented at the American Society of Retina Specialists 2024 in Stockholm, Sweden, show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.

Data in early-stage patients was presented at 42nd American Society of Retina Specialists Annual Scientific Meeting, being held in Stockholm, Sweden.

The purpose of the study was to determine if experience affects the surgeons’ dexterity response to pharmacologic and behavioral interventions.

Novice surgeons affected more than seasoned surgeons

Researchers indicate that minimally invasive treatment with NurExon Biologic’s ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals.

Carl C Awh, MD, FASRS, sat down with Hattie Hayes, Editor of Ophthalmology Times Europe, to discuss the first readout of the Phase 3 PAGODA trial at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Theodore Leng, MD, MS, speaks about his ASRS presentation, focusing on the FARETINA-DME Study

Rishi P. Singh, MD, sat down with Sydney Crago, Editor of Modern Retina, to discuss his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Durga Borkar, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss her presentation on Fas inhibition with ONL1204 for the Treatment of Geographic Atrophy and the first-time results From a Phase 1b study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Theodore Lang, MD, MS, sat down to discuss his presentation on the FARETINA-DME Study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Ahead of the ASRS meeting, Rishi P. Singh, MD, previews results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy

Carl C. Awh, MD, FASRS, gives an overview of the Phase 3 Pagoda trial year 2 results

Answers to common questions that can help kick-start the journey into the metaverse to learn from the many virtual educational meetings and conference opportunities while mingling with colleagues worldwide.

Carl J. Danzig, MD, discusses efficacy, safety, and durability of faricimab in macular oedema due to retinal vein occlusion (RVO).

Martin Zinkernagel, MD, PhD, sat down with Hattie Hayes, Editor of Ophthalmology Times Europe, to discuss his time on the sustainability expert panel Study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Carl Danzig, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on the 72-Week results from the Phase 3 BALATON and COMINO trials at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

This year, the ASRS meeting will feature an expert panel on sustainability — learn more from panelist Martin Zinkernagel, MD, PhD